Your Opportunity to Optimize Your ADC’s 91AV
As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and conjugation technologies have become the single-biggest area of investment for ADC drug developers.
The inaugural ADC Linker & Conjugation Summit will provide an in-depth focus on all things linker and conjugation chemistry, with insights from the leading minds within the ADC community working in discovery and process chemistry through to conjugation. Leave this meeting empowered to optimize
your ADCs chemistry to bring ADCs with a wider therapeutic index to patients.
Join 80+ peers including Seagen, Genentech, Bolt Biotherapeutics, and many more in Boston this August, to aid the development of stable ADCs with a widened therapeutic index.
As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and conjugation technologies have become the single-biggest area of investment for ADC drug developers.
The inaugural ADC Linker & Conjugation Summit will provide an in-depth focus on all things linker and conjugation chemistry, with insights from the leading minds within the ADC community working in discovery and process chemistry through to conjugation. Leave this meeting empowered to optimize
your ADCs chemistry to bring ADCs with a wider therapeutic index to patients.
Join 80+ peers including Seagen, Genentech, Bolt Biotherapeutics, and many more in Boston this August, to aid the development of stable ADCs with a widened therapeutic index.
